Molecular Templates, Inc.

The momentum for this stock is not very good. Molecular Templates, Inc. is not a good value stock. Molecular Templates, Inc. is not a good growth stock. Molecular Templates, Inc. is a mediocre stock to choose.
Log in to see more information.
Molecular Templates, Inc. is a clinical stage biopharmaceutical company, which engages in the discov...
MTEM Fundamental Data by TradingView

News

MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024
MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nMTEM stock results show that Molecular Templates beat analyst estimates for earnings per share and beat on revenue for the second...\n more…

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

Globe Newswire Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of...\n more…

Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry
Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

Simply Wall St Those holding Molecular Templates, Inc. ( NASDAQ:MTEM ) shares would be relieved that the share price has rebounded 27...\n more…

Molecular Templates, Inc. (NASDAQ:MTEM) Short Interest Down 30.7% in June
Molecular Templates, Inc. (NASDAQ:MTEM) Short Interest Down 30.7% in June

Zolmax Molecular Templates, Inc. (NASDAQ:MTEM - Get Free Report) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 128,000 shares, a...\n more…

Molecular Templates provides update on clinical-stage programs
Molecular Templates provides update on clinical-stage programs

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Provides Interim Update

Globe Newswire Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169...\n more…